Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis A (inactivated) and hepatitis B (recombinant) vaccine (Sinovac Biotech Ltd.)
- Development stage
- Phase 4
- Lead developer
- Sinovac Biotech
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Bilive is a combined vaccine developed by Sinovac Biotech for the simultaneous prevention of hepatitis A and hepatitis B. It is formulated by mixing inactivated hepatitis A virus (the same component used in Sinovac's Healive vaccine) with recombinant hepatitis B surface antigen (HBsAg). The hepatitis A component is derived from the TZ8 strain, cultivated in human diploid cells and inactivated with formaldehyde. The hepatitis B component is a recombinant protein expressed in yeast (*Saccharomyces cerevisiae*). The vaccine is adsorbed onto aluminum hydroxide as an adjuvant. Bilive is primarily used in China and is designed to provide a more convenient immunization schedule by reducing the number of injections required to protect against both viral pathogens, particularly in infants and high-risk populations.
- Brand names
- Bilive
- Other names
- Healive-Sinovac Biotech Co., Ltd-hepatitis A-hepatitis BSinovac combined hepatitis A and B vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on hepatitis A (inactivated) and hepatitis B (recombinant) vaccine (Sinovac Biotech Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis A (inactivated) and hepatitis B (recombinant) vaccine (Sinovac Biotech Ltd.).